It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The molecular basis of disease progression from UV-induced precancerous actinic keratosis (AK) to malignant invasive cutaneous squamous cell carcinoma (cSCC) and potentially lethal metastatic disease remains unclear. DNA sequencing studies have revealed a massive mutational burden but have yet to illuminate mechanisms of disease progression. Here we perform RNAseq transcriptomic profiling of 110 patient samples representing normal sun-exposed skin, AK, primary and metastatic cSCC and reveal a disease continuum from a differentiated to a progenitor-like state. This is accompanied by the orchestrated suppression of master regulators of epidermal differentiation, dynamic modulation of the epidermal differentiation complex, remodelling of the immune landscape and an increase in the preponderance of tumour specific keratinocytes. Comparative systems analysis of human cSCC coupled with the generation of genetically engineered murine models reveal that combinatorial sequential inactivation of the tumour suppressor genes Tgfbr2, Trp53, and Notch1 coupled with activation of Ras signalling progressively drives cSCC progression along a differentiated to progenitor axis. Taken together we provide a comprehensive map of the cSCC disease continuum and reveal potentially actionable events that promote and accompany disease progression.
The process by which actinic keratosis differentiates to malignant invasive cutaneous squamous cell carcinoma is unclear. Here, the authors use RNA-seq to illustrate a disease continuum between the two states, and use in vivo models to confirm the role of Tgfbr2, Trp53, and Notch1 in this process.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details















1 University of Glasgow, School of Cancer Sciences, Glasgow, UK (GRID:grid.8756.c) (ISNI:0000 0001 2193 314X); University of Heidelberg, Department of Surgery, Heidelberg, Germany (GRID:grid.7700.0) (ISNI:0000 0001 2190 4373); University Clinic Heidelberg, Section Surgical Research, Heidelberg, Germany (GRID:grid.5253.1) (ISNI:0000 0001 0328 4908)
2 Cancer Research UK Beatson Institute, Glasgow, UK (GRID:grid.23636.32) (ISNI:0000 0000 8821 5196)
3 Cancer Research UK Beatson Institute, Glasgow, UK (GRID:grid.23636.32) (ISNI:0000 0000 8821 5196); University of Edinburgh, Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988)
4 Cancer Research UK Beatson Institute, Glasgow, UK (GRID:grid.23636.32) (ISNI:0000 0000 8821 5196); University of Edinburgh, Edinburgh Medical School, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988)
5 University of Glasgow, School of Cancer Sciences, Glasgow, UK (GRID:grid.8756.c) (ISNI:0000 0001 2193 314X); Cancer Research UK Beatson Institute, Glasgow, UK (GRID:grid.23636.32) (ISNI:0000 0000 8821 5196)
6 University of Glasgow, School of Cancer Sciences, Glasgow, UK (GRID:grid.8756.c) (ISNI:0000 0001 2193 314X)
7 Queen Mary University of London, Faculty of Medicine and Dentistry, London, UK (GRID:grid.4868.2) (ISNI:0000 0001 2171 1133)
8 Queen Mary University of London, Faculty of Medicine and Dentistry, London, UK (GRID:grid.4868.2) (ISNI:0000 0001 2171 1133); Department of Dermatology, Royal London Hospital, Barts Health NHS Trust, London, UK (GRID:grid.416041.6) (ISNI:0000 0001 0738 5466)
9 St John’s Institute of Dermatology, St Thomas’s Hospital, London, UK (GRID:grid.425213.3)
10 Cancer Research UK Beatson Institute, Glasgow, UK (GRID:grid.23636.32) (ISNI:0000 0000 8821 5196); German Cancer Research Centre (DKFZ), Heidelberg, Germany (GRID:grid.7497.d) (ISNI:0000 0004 0492 0584)
11 1st Department of Dermatology and Venereology, Andreas Sygros Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece (GRID:grid.5216.0) (ISNI:0000 0001 2155 0800)
12 University of of California at San Francisco, Department of Dermatology, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811)
13 University of Dundee, Molecular and Clinical Medicine, School of Medicine, Dundee, UK (GRID:grid.8241.f) (ISNI:0000 0004 0397 2876)